Novogen (NASDAQ:KZIA) Cut to “Hold” at Wall Street Zen

Wall Street Zen downgraded shares of Novogen (NASDAQ:KZIA) from a buy rating to a hold rating in a report released on Sunday morning.

Several other equities analysts have also recently issued reports on KZIA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Novogen in a research report on Thursday, January 22nd. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Novogen in a report on Wednesday, January 28th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Novogen has a consensus rating of “Hold” and an average target price of $19.00.

Novogen Trading Up 3.6%

NASDAQ KZIA opened at $8.52 on Friday. Novogen has a 12 month low of $2.86 and a 12 month high of $17.40. The company’s 50 day simple moving average is $6.75 and its 200 day simple moving average is $7.78.

Novogen Company Profile

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.